Nalaganje...

Soluble CD105 is prognostic of disease recurrence in prostate cancer patients

While the overall five-year survival rate for prostate cancer is near 100%, up to 35% of patients will develop recurrent disease. At the time of prostatectomy, prostate specific antigen (PSA) is used to guide primary therapy with the goal of curative intervention. It can be valuable to know when pri...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Endocr Relat Cancer
Main Authors: Placencio-Hickok, Veronica R., Madhav, Anisha, Kim, Sungjin, Duong, Frank, Angara, Bryan, Liu, Zhenqiu, Bhowmick, Neil A.
Format: Artigo
Jezik:Inglês
Izdano: 2020
Teme:
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC7002242/
https://ncbi.nlm.nih.gov/pubmed/31648185
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1530/ERC-19-0370
Oznake: Označite
Brez oznak, prvi označite!